2025 H2 -tulosraportti
86 päivää sitten
‧38 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 062 | - | - | ||
| 2 938 | - | - | ||
| 1 | - | - | ||
| 1 477 | - | - | ||
| 2 696 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sittenHi again, Thor Medical is still a pure medical company that is building the AlphaOne factory at Herøya for the production of thorium-228 (Th-228) for Targeted Alpha Therapy (TAT), a promising new cancer treatment. Production start is planned for Q3 2026, and they already have a solid order book of around 850 mill. NOK. What is worth noting right now is that the same Norwegian thorium raw material (Th-232 from Fensfeltet via Rare Earths Norway) is also in play on the energy side: According to a recent article, Copenhagen Atomics and the Norwegian company Ocean-Power have entered into an MoU to explore the development of thorium-based molten salt reactors (MSR) in Norway already in the 2030s. The goal is to produce green electricity and heat with compact, factory-built reactors. Article: https://energiwatch.no/nyheter/fornybar/article19321137.ece Rare Earths Norway has previously entered into LoI with both Thor Medical (medicine) and Copenhagen Atomics (energy). This means that the same thorium source can be used in two completely different value chains. This is not TRMED's strategy as of today. The company is 100% focused on medicine today. But it shows that Norway could potentially get a thorium ecosystem that covers both medicine and future nuclear power. Interesting to follow for those interested in thorium technology in general. Have a good weekend🫡- ·1 päivä sitten · MuokattuBrief summary from Grok AI: TRMED's thorium supply chain is not just medicine (TAT cancer treatment via AlphaOne Q3 2026) — it is also a strategic bridge to future thorium molten salt reactors (MSR) (via the Rare Earths Norway agreements with Copenhagen Atomics, the IMSR ecosystem, etc.). The dual effect (medical isotopes today + raw material for clean energy tomorrow) is exactly the type of real thorium infrastructure that can accelerate MSR rollout… which, as you've said all along, is extremely beneficial for AI — because it provides the massive, stable power hyperscalers need for their data centers.
·1 päivä sittenI have posted something like this before because I see a red thread here. If one looks at who is in the Companies that are in the same "thorium industry" then it starts to become interesting. Thorium can be used for so much. I believe something was tested in the reactor in Halden before it was shut down. There was probably one company that is "frozen" I seem to recall. Also with a red thread further on 😉 
·1 päivä sitten · MuokattuAmateur analysis: The factory has now been handed over to TM. They have recently advertised two positions. A little unsure how relevant they are in relation to the start-up of production. But let's say they are key personnel, then I believe start-up within q3 is within reach. Overall, things indicate that the processes are going according to plan. The stock probably needs news to go up significantly. It has been green for a few days now, perhaps that could be a premonition. I believe we are heading for good times.- ·1 päivä sittenHere it can go just as fast as with Sivers Semiconductors.. That it can, doesn't mean it will, but everything is set for it.·1 päivä sittenCan you explain why you draw that parallel?·12 t sittenVery relevant for future prospects regarding medicine+power. Some see the product today, as it is, while others see future use of the same 'product' in several sectors. So you can base your decisions on whichever you want. Personally, I see this as very exciting for the future.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
86 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenHi again, Thor Medical is still a pure medical company that is building the AlphaOne factory at Herøya for the production of thorium-228 (Th-228) for Targeted Alpha Therapy (TAT), a promising new cancer treatment. Production start is planned for Q3 2026, and they already have a solid order book of around 850 mill. NOK. What is worth noting right now is that the same Norwegian thorium raw material (Th-232 from Fensfeltet via Rare Earths Norway) is also in play on the energy side: According to a recent article, Copenhagen Atomics and the Norwegian company Ocean-Power have entered into an MoU to explore the development of thorium-based molten salt reactors (MSR) in Norway already in the 2030s. The goal is to produce green electricity and heat with compact, factory-built reactors. Article: https://energiwatch.no/nyheter/fornybar/article19321137.ece Rare Earths Norway has previously entered into LoI with both Thor Medical (medicine) and Copenhagen Atomics (energy). This means that the same thorium source can be used in two completely different value chains. This is not TRMED's strategy as of today. The company is 100% focused on medicine today. But it shows that Norway could potentially get a thorium ecosystem that covers both medicine and future nuclear power. Interesting to follow for those interested in thorium technology in general. Have a good weekend🫡
- ·1 päivä sitten · MuokattuBrief summary from Grok AI: TRMED's thorium supply chain is not just medicine (TAT cancer treatment via AlphaOne Q3 2026) — it is also a strategic bridge to future thorium molten salt reactors (MSR) (via the Rare Earths Norway agreements with Copenhagen Atomics, the IMSR ecosystem, etc.). The dual effect (medical isotopes today + raw material for clean energy tomorrow) is exactly the type of real thorium infrastructure that can accelerate MSR rollout… which, as you've said all along, is extremely beneficial for AI — because it provides the massive, stable power hyperscalers need for their data centers.·1 päivä sittenI have posted something like this before because I see a red thread here. If one looks at who is in the Companies that are in the same "thorium industry" then it starts to become interesting. Thorium can be used for so much. I believe something was tested in the reactor in Halden before it was shut down. There was probably one company that is "frozen" I seem to recall. Also with a red thread further on 😉
- ·1 päivä sitten · MuokattuAmateur analysis: The factory has now been handed over to TM. They have recently advertised two positions. A little unsure how relevant they are in relation to the start-up of production. But let's say they are key personnel, then I believe start-up within q3 is within reach. Overall, things indicate that the processes are going according to plan. The stock probably needs news to go up significantly. It has been green for a few days now, perhaps that could be a premonition. I believe we are heading for good times.
- ·1 päivä sittenHere it can go just as fast as with Sivers Semiconductors.. That it can, doesn't mean it will, but everything is set for it.·1 päivä sittenCan you explain why you draw that parallel?·12 t sittenVery relevant for future prospects regarding medicine+power. Some see the product today, as it is, while others see future use of the same 'product' in several sectors. So you can base your decisions on whichever you want. Personally, I see this as very exciting for the future.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 062 | - | - | ||
| 2 938 | - | - | ||
| 1 | - | - | ||
| 1 477 | - | - | ||
| 2 696 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
2025 H2 -tulosraportti
86 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenHi again, Thor Medical is still a pure medical company that is building the AlphaOne factory at Herøya for the production of thorium-228 (Th-228) for Targeted Alpha Therapy (TAT), a promising new cancer treatment. Production start is planned for Q3 2026, and they already have a solid order book of around 850 mill. NOK. What is worth noting right now is that the same Norwegian thorium raw material (Th-232 from Fensfeltet via Rare Earths Norway) is also in play on the energy side: According to a recent article, Copenhagen Atomics and the Norwegian company Ocean-Power have entered into an MoU to explore the development of thorium-based molten salt reactors (MSR) in Norway already in the 2030s. The goal is to produce green electricity and heat with compact, factory-built reactors. Article: https://energiwatch.no/nyheter/fornybar/article19321137.ece Rare Earths Norway has previously entered into LoI with both Thor Medical (medicine) and Copenhagen Atomics (energy). This means that the same thorium source can be used in two completely different value chains. This is not TRMED's strategy as of today. The company is 100% focused on medicine today. But it shows that Norway could potentially get a thorium ecosystem that covers both medicine and future nuclear power. Interesting to follow for those interested in thorium technology in general. Have a good weekend🫡
- ·1 päivä sitten · MuokattuBrief summary from Grok AI: TRMED's thorium supply chain is not just medicine (TAT cancer treatment via AlphaOne Q3 2026) — it is also a strategic bridge to future thorium molten salt reactors (MSR) (via the Rare Earths Norway agreements with Copenhagen Atomics, the IMSR ecosystem, etc.). The dual effect (medical isotopes today + raw material for clean energy tomorrow) is exactly the type of real thorium infrastructure that can accelerate MSR rollout… which, as you've said all along, is extremely beneficial for AI — because it provides the massive, stable power hyperscalers need for their data centers.·1 päivä sittenI have posted something like this before because I see a red thread here. If one looks at who is in the Companies that are in the same "thorium industry" then it starts to become interesting. Thorium can be used for so much. I believe something was tested in the reactor in Halden before it was shut down. There was probably one company that is "frozen" I seem to recall. Also with a red thread further on 😉
- ·1 päivä sitten · MuokattuAmateur analysis: The factory has now been handed over to TM. They have recently advertised two positions. A little unsure how relevant they are in relation to the start-up of production. But let's say they are key personnel, then I believe start-up within q3 is within reach. Overall, things indicate that the processes are going according to plan. The stock probably needs news to go up significantly. It has been green for a few days now, perhaps that could be a premonition. I believe we are heading for good times.
- ·1 päivä sittenHere it can go just as fast as with Sivers Semiconductors.. That it can, doesn't mean it will, but everything is set for it.·1 päivä sittenCan you explain why you draw that parallel?·12 t sittenVery relevant for future prospects regarding medicine+power. Some see the product today, as it is, while others see future use of the same 'product' in several sectors. So you can base your decisions on whichever you want. Personally, I see this as very exciting for the future.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 062 | - | - | ||
| 2 938 | - | - | ||
| 1 | - | - | ||
| 1 477 | - | - | ||
| 2 696 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt